Explore the need to shift from a reactive treatment-based approach to proactive, value-based renal care management. Also, identify innovative solutions with high potential, short- and long-term growth opportunities for medical devices, and technology participants.
Take an in-depth look at the biologics drug development pipeline and capacity expansion plans of biologics contract development and manufacturing organizations (CDMOs) and biopharmaceutical companies. Gain strategic insights on the bioprocessing industry.
This research analyzes the major segments of this sector, including basic, surgical, and advanced wound care solutions. It also examines the impact of new-age, AI-based solutions such as 3D-bioprinted scaffolds, sensor-embedded early detection scanners, autologous wound patches, etc.
Due to the global pandemic, we are living in unprecedented times. This pandemic has proven to be the ultimate iconoclasm across industries. Everything is on the anvil, from business attire to face-to-face meetings to the need to have a permanent office. Sustainable energy is no different. When the pandemic set in and oil prices plummeted, the most common belief was that the investments in sustainable energy will slow down, the new wave of electrification in automotive will subside and we will turn the clock back on the climate agenda.
Prolonged lockdowns in several countries turned out to be an unprecedented social experiment. When the transport and industrial emissions stopped, urban air quality drastically improved in a matter of days. That underlined the harmful effects of the emissions.
1. Sales of electric vehicles (EV) continue unabated. In countries like Germany, EV penetration has exploded.
2. As per the International Energy Agency (IEA), electricity generation by renewable sources grew against the decline in other conventional energy sources.
3. Investments in renewable energy and new zero-carbon fuels like hydrogen increased multi-fold.
Schedule a dialog or email us at firstname.lastname@example.org to connect with an industry expert at no charge. We are taking unprecedented action to make our team available to help you cut through the media and politics to get factual one-to-one guidance for the issues and opportunities that matter most to your business.
Frost & Sullivan's latest white paper, Improving Patient Care with the Smith+Nephew LEAF Patient Monitoring System, discusses the significant problem of hospital-acquired pressure injuries, the operational and economic impacts of HAPIs on providers, and the potential benefits that a patient-worn sensor solution can bring to managing the condition more effectively.
The shift to value-based care relies heavily on evidence-based medicine, and pharmaceutical companies play an important role in scientific communication across the healthcare ecosystem. Medical affairs experts interact with healthcare professionals to understand patients’ needs, interpret scientific data regarding therapeutic options, and then engage providers with hyper-relevant communication to help them make informed decisions.
SPAC (Special Purpose Acquisition Company) is emerging as a popular route that enables companies to join public stock markets without going through the IPO process, with digital health certainly riding this wave. The first two months of 2021 saw 144 SPACs, raising $44 billion, with ten digital health deals in the first quarter of 2021, including Revolution Healthcare, Blueprint Health Merger.
Frost & Sullivan’s recent analysis, 'Global RNA Therapeutics: Technology Growth Opportunities', reveals that ribonucleic acid (RNA) therapeutics is poised to gain momentum in the next few years and can potentially be applied to a wide variety of disease interventions. Additionally, the growth opportunities exposed by the initial commercialization of mRNA vaccines, antisense oligonucleotides (ASOs) and short interfering RNA (siRNA)-based therapeutics are further attracting pharmaceutical and biotechnology companies to invest in this space and expedite research and development (R&D).
The dynamics of the COVID-19 pandemic, including multi-country shutdowns, put an excessive amount of pressure on healthcare supply chains worldwide. There are clear signs that the pandemic will be here in the long run, driving healthcare companies to address supply chain vulnerabilities. Pharmaceutical companies relied heavily on an unprecedented level of cooperation from raw material suppliers, government agencies, and contract development and manufacturing organizations.
With the rising number of stakeholders playing a role in medical decision-making, pharmaceutical companies are looking for more effective ways to communicate the value of an innovative treatment. They are increasingly turning to actionable, evidence-based programs to convince these stakeholders of the value of the treatment. A comprehensive data set can help an analytics team map a treatment journey and quickly identify the patients and physicians who are most likely to benefit from a novel therapy.Read more